Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CADL Candel Therapeutics, Inc.

Closed 10-16 16:00:00 EDT

8.19

-0.72

-8.08%

盘后8.19

+0.00+0.05%

19:52 EDT

High8.92	Low8.13	Vol1.51M
Open8.92	D1 Closing8.91	Amplitude8.92%
Mkt Cap626.69M	Tradable Cap491.87M	Total Shares76.52M
T/O12.69M	T/O Rate2.52%	Tradable Shares60.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CADL","market":"US","secType":"STK","nameCN":"Candel Therapeutics, Inc.","latestPrice":8.19,"timestamp":1792180800000,"preClose":8.91,"halted":0,"volume":1513092,"hourTrading":{"tag":"盘后","latestPrice":8.1938,"preClose":8.19,"latestTime":"19:52 EDT","volume":35101,"amount":287851.591,"timestamp":1792194764211,"change":0.0038,"changeRate":0.000464,"amplitude":0.010989},"delay":0,"changeRate":-0.08080808080808088,"floatShares":60056800,"shares":76518600,"eps":-1.438968,"marketStatus":"Closed","change":-0.72,"latestTime":"10-16 16:00:00 EDT","open":8.92,"high":8.92,"low":8.125,"amount":12692768.943959998,"amplitude":0.089226,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.438968,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1792396800000},"marketStatusCode":5,"adr":0,"listingDate":1627358400000,"exchange":"NASDAQ","adjPreClose":8.91,"preHourTrading":{"tag":"盘前","latestPrice":8.92,"preClose":8.91,"latestTime":"09:29 EDT","volume":1347,"amount":11997.188853,"timestamp":1792157399988,"change":0.01,"changeRate":0.001122,"amplitude":0.003367},"postHourTrading":{"tag":"盘后","latestPrice":8.1938,"preClose":8.19,"latestTime":"19:52 EDT","volume":35101,"amount":287851.591,"timestamp":1792194764211,"change":0.0038,"changeRate":0.000464,"amplitude":0.010989},"volumeRatio":1.653673,"impliedVol":1.2338,"impliedVolPercentile":0.6932},"requestUrl":"/m/hq/s/CADL","defaultTab":"news","newsList":[{"id":"2672712822","title":"Candel Therapeutics to Present NSCLC Aglatimagene Besadenovec Study Data at SITC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2672712822","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672712822?lang=en_us&edition=fundamental","pubTime":"2026-10-02 21:00","pubTimestamp":1790946058,"startTime":"0","endTime":"0","summary":"Candel Therapeutics to present NSCLC aglatimagene besadenovec study data at SITC 2026Candel Therapeutics set two poster presentations at SITC’s 41st Annual Meeting, November 4-8, 2026 in Phoenix.Resul","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDLfkxys:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014039.USD","SG9999014013.SGD","BK4112","IE00BQXX3F31.USD","LU2210150020.SGD","IE00BQXX3D17.EUR","LU2210149790.SGD","BK4588","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","BCDF","IE00B64PRP62.GBP","CADL","LU0314104364.USD","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","IE00BKPKM429.USD","BK4139","BK4539","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672591712","title":"Candel Therapeutics to Present at the SITC 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2672591712","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672591712?lang=en_us&edition=fundamental","pubTime":"2026-10-02 21:00","pubTimestamp":1790946000,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., Oct.  02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/02/3373820/0/en/candel-therapeutics-to-present-at-the-sitc-2026-annual-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0003851619.USD","DNA","HYLG","01308","IE0003795394.USD","IE00B12V2V27.USD","SEA","SG9999011746.SGD","IE00BYTNYN87.SGD","BK1541","BK4121","MEDX","CADL","IE00BYQNZ168.SGD","BK4109","BK4539","BOAT","BK4231","GDOC","LU1880383366.USD","BK4080","IDNA","BK1103","LU1880383440.USD","BK4139","SITC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672076495","title":"Candel Therapeutics Grants Inducement Stock Options for 85,900 Shares to Four New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2672076495","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672076495?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:05","pubTimestamp":1790885146,"startTime":"0","endTime":"0","summary":"Candel Therapeutics grants inducement stock options for 85,900 shares to four new employeesCandel Therapeutics granted inducement stock options covering 85,900 common shares to four new employees on S","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL2nn0Fb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","BCDF","LU2210150020.SGD","BK4112","LU0314104364.USD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BN0W2W23.USD","CADL","BK4139","IE00BKPKM429.USD","BK4539","SG9999014013.SGD","LU2095319765.USD","SG9999014021.USD","IE00BQXX3C00.GBP","SG9999014039.USD","SG9999014005.SGD","BK4585","IE00BN0W2T93.GBP","NDAQ","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","BK4588","IE00BN0W2V16.EUR","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672605764","title":"Candel Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672605764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672605764?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:05","pubTimestamp":1790885101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUABBQHGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672640197","title":"Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672640197","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672640197?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:05","pubTimestamp":1790885100,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., Oct.  01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3373373/0/en/candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4539","BK4139","LCLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672754023","title":"Candel Therapeutics Phase 2a NSCLC Study Shows 24.5-Month Median Overall Survival for Aglatimagene Plus Valacyclovir After ICI Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2672754023","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672754023?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:06","pubTimestamp":1790856377,"startTime":"0","endTime":"0","summary":"Candel Therapeutics phase 2a NSCLC study shows 24.5-month median overall survival for aglatimagene plus valacyclovir after ICI failureCandel Therapeutics reported final Phase 2a results in advanced NS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL6Rphwx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014021.USD","SG9999014005.SGD","BCDF","LU2210150020.SGD","SG9999014013.SGD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","LU2210149790.SGD","IE00BKPKM429.USD","BK4539","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BGHQF748.EUR","BK4112","NDAQ","IE00BQXX3C00.GBP","LU2095319765.USD","CADL","IE00BN0W2V16.EUR","BK4139","BK4588","BK4585","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672754046","title":"Candel Therapeutics - 69% of Patients with Multiple Lesions Show Systemic Clinical Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2672754046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672754046?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:06","pubTimestamp":1790856373,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N0OU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CADL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672275404","title":"Candel Therapeutics - Aglatimagene Plus Valacyclovir Well Tolerated; Grade 3 Adverse Events in 13.7% of Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2672275404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672275404?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:06","pubTimestamp":1790856373,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N0OU:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672044754","title":"Candel Therapeutics - Phase 2a Trial Shows Median Overall Survival of 24.5 Months in Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2672044754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672044754?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:06","pubTimestamp":1790856373,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N0OU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672554507","title":"Alec Stranahan Reiterates Buy on Candel Therapeutics, Maintains $18 Price Target Amid Advancing Prostate Cancer Program and 2026 BLA Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2672554507","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672554507?lang=en_us&edition=fundamental","pubTime":"2026-10-01 17:35","pubTimestamp":1790847342,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Candel Therapeutics, with a price target ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alec-stranahan-reiterates-buy-on-candel-therapeutics-maintains-18-price-target-amid-advancing-prostate-cancer-program-and-2026-bla-milestone-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alec-stranahan-reiterates-buy-on-candel-therapeutics-maintains-18-price-target-amid-advancing-prostate-cancer-program-and-2026-bla-milestone-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671201198","title":"Candel Therapeutics Reports Phase 3 Prostate Cancer Biomarker Data Showing Sustained Immune Remodeling After Aglatimagene Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2671201198","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671201198?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:08","pubTimestamp":1790770092,"startTime":"0","endTime":"0","summary":"Candel Therapeutics reports phase 3 prostate cancer biomarker data showing sustained immune remodeling after aglatimagene treatmentCandel Therapeutics disclosed new biomarker data from its completed p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDLlRxQT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014039.USD","BK4139","IE00BGHQF748.EUR","BK4539","CADL","LU2095319765.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","BK4585","BK4112","IE00BQXX3C00.GBP","BCDF","LU0314104364.USD","SG9999014021.USD","IE00BN0W2W23.USD","SG9999014005.SGD","NDAQ","IE00BQXX3F31.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671921201","title":"Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at Astro 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2671921201","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671921201?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:05","pubTimestamp":1790769900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUA34LJ63:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669955160","title":"Candel Therapeutics Shares Rise After BofA Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2669955160","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669955160?lang=en_us&edition=fundamental","pubTime":"2026-09-22 02:37","pubTimestamp":1790015866,"startTime":"0","endTime":"0","summary":"Candel Therapeutics (CADL) shares rose 3.9% in Monday trading after BofA upgraded the stock to buy from neutral.Trading volume stood at 631,000 shares, compared with a daily average of about 1.4 million.Price: 11.27, Change: +0.42, Percent Change: +3.88","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669670891","title":"H.C. Wainwright Remains a Buy on Candel Therapeutics (CADL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669670891","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669670891?lang=en_us&edition=fundamental","pubTime":"2026-09-22 01:56","pubTimestamp":1790013364,"startTime":"0","endTime":"0","summary":"In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Candel Therapeutics, with a price target of $23.00....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-candel-therapeutics-cadl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-candel-therapeutics-cadl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CADL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150897","title":"BofA Upgrades Candel Therapeutics to Buy From Neutral, Price Target is $18","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150897","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150897?lang=en_us&edition=fundamental","pubTime":"2026-09-21 18:53","pubTimestamp":1789987987,"startTime":"0","endTime":"0","summary":"Candel Therapeutics (CADL) has an average rating of buy and mean price target of $21.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669981150","title":"Candel Therapeutics upgraded to Buy from Neutral at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2669981150","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669981150?lang=en_us&edition=fundamental","pubTime":"2026-09-21 18:40","pubTimestamp":1789987240,"startTime":"0","endTime":"0","summary":"BofA upgraded Candel Therapeutics (CADL) to Buy from Neutral with a price target of $18, up from $12. A mature prostate cancer package, on track fo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-upgraded-to-buy-from-neutral-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-upgraded-to-buy-from-neutral-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666572249","title":"Candel Therapeutics CEO Paul Peter Tak Disposes of Common Shares Worth $3,164,815.85","url":"https://stock-news.laohu8.com/highlight/detail?id=2666572249","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666572249?lang=en_us&edition=fundamental","pubTime":"2026-09-12 06:12","pubTimestamp":1789164760,"startTime":"0","endTime":"0","summary":"Candel Therapeutics CEO Paul Peter Tak disposes of common shares worth $3,164,815.85Paul Peter Tak, Chief Executive Officer, cut his direct stake in Candel Therapeutics to 113,321 shares.Disposed of 280,245 shares on Sep. 10-11 at weighted average prices of $11.5 and $10.46.Exercised options for 125,000 shares at $1.55 on Sep. 10.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL7GNqtL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Candel Therapeutics CEO Paul Peter Tak Disposes of Common Shares Worth $3,164,815.85","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666515151","title":"Candel Therapeutics Director Martine Zimmermann Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2666515151","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666515151?lang=en_us&edition=fundamental","pubTime":"2026-09-11 04:22","pubTimestamp":1789071742,"startTime":"0","endTime":"0","summary":"Candel Therapeutics director Martine Zimmermann files initial beneficial ownership statementMartine Zimmermann filed an initial Form 3 as a director of Candel Therapeutics on Sept. 8, 2026.Disclaimer:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL259g1Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CADL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666963515","title":"Candel Therapeutics Adds Independent Director to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2666963515","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666963515?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:48","pubTimestamp":1789044520,"startTime":"0","endTime":"0","summary":"Candel Therapeutics ( ($CADL) ) has shared an announcement. On September 6, 2026, Candel Therapeutics’ board expanded from ten to eleven members an...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-adds-independent-director-to-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-adds-independent-director-to-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666593868","title":"Candel Therapeutics Appoints Martine Zimmermann, Pharmd, to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2666593868","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666593868?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:05","pubTimestamp":1789041900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA6TWHFL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.candeltx.com","stockEarnings":[{"period":"1week","weight":-0.0776},{"period":"1month","weight":-0.1987},{"period":"3month","weight":-0.1248},{"period":"6month","weight":0.3987},{"period":"1year","weight":0.4912},{"period":"ytd","weight":0.577}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.019},{"period":"3month","weight":0.0383},{"period":"6month","weight":0.0868},{"period":"1year","weight":0.1603},{"period":"ytd","weight":0.1318}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.056687},{"month":2,"riseRate":0.4,"avgChangeRate":0.052018},{"month":3,"riseRate":0.2,"avgChangeRate":-0.120448},{"month":4,"riseRate":0.4,"avgChangeRate":0.650234},{"month":5,"riseRate":1,"avgChangeRate":0.18781},{"month":6,"riseRate":0.2,"avgChangeRate":-0.088023},{"month":7,"riseRate":0.2,"avgChangeRate":0.003189},{"month":8,"riseRate":0.833333,"avgChangeRate":0.108437},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.047745},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.116297},{"month":11,"riseRate":0,"avgChangeRate":-0.079739},{"month":12,"riseRate":0.8,"avgChangeRate":0.288433}],"exchange":"NASDAQ","name":"Candel Therapeutics, Inc.","nameEN":"Candel Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Candel Therapeutics, Inc.,CADL,Candel Therapeutics, Inc.股票,Candel Therapeutics, Inc.股票老虎,Candel Therapeutics, Inc.股票老虎国际,Candel Therapeutics, Inc.行情,Candel Therapeutics, Inc.股票行情,Candel Therapeutics, Inc.股价,Candel Therapeutics, Inc.股市,Candel Therapeutics, Inc.股票价格,Candel Therapeutics, Inc.股票交易,Candel Therapeutics, Inc.股票购买,Candel Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}